Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

Next Previous
Trial Profile

Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use
  • Acronyms MAP-X; MAPX; mOIT MAP-X

    • Most Recent Events

    • 28 Feb 2022 Results evaluating the difference in OIT-related allergic adverse events (AEs) between home versus clinic dose among participants who received omalizumab in randomized phase 2 studies MAPX and MIMIX, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 28 Feb 2022 Results (n=42) investigating predictors of successful desensitization, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 30 Mar 2021 Results assessing Immune Changes Beyond Th2 Pathways During Rapid Multifood Immunotherapy enabled with Omalizumab published in the Allergy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top